Keyphrases
Activated Factor VII
14%
Adverse Events
28%
Coagulation Testing
14%
Computed Tomography
14%
Consumption Coagulopathy
14%
Deep Vein Thrombosis
14%
Doppler Ultrasonography
14%
Dose-escalation Trial
14%
Edema
28%
Fever
14%
Glasgow Coma Scale
14%
Hematoma Growth
28%
Hemorrhage Volume
42%
Hemostasis
14%
Intracerebral Hemorrhage
100%
Lower Extremity
14%
Myocardial Ischemia
14%
National Institutes of Health Stroke Scale (NIHSS)
14%
Onset to Treatment
14%
Phase II Trial
14%
Placebo
28%
Placebo-controlled
14%
Randomized Double-blind
14%
Rash
14%
Recombinant Activated Factor VII (rFVIIa)
100%
Safety Assessment
14%
Safety Concerns
14%
Serial Electrocardiography
14%
Serious Adverse Events
14%
Spontaneous Intracerebral Hemorrhage
100%
T-wave Inversion
14%
Treatment-related
14%
Troponin
14%
Vascular Injury
14%
Volume Ratio
14%
Vomiting
14%
Medicine and Dentistry
Adverse Event
33%
Blood Stasis
11%
Blood Vessel Injury
11%
Cerebral Hemorrhage
100%
Coagulation Testing
11%
Computer Assisted Tomography
11%
Deep Vein Thrombosis
11%
Disseminated Intravascular Coagulation
11%
Doppler Ultrasound
11%
Edema
22%
Electrocardiography
22%
Exanthem
11%
Factor VII
11%
Glasgow Coma Scale
11%
Heart Muscle Ischemia
11%
Hematoma
22%
National Institutes of Health Stroke Scale
11%
Phase II Trials
11%
Placebo
33%
Recombinant Blood Clotting Factor 7a
100%
Safety Assessment
11%
T Wave Inversion
11%
Troponin I
11%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
33%
Blood Clotting Factor 7
11%
Blood Stasis
11%
Blood Vessel Injury
11%
Brain Hemorrhage
100%
Cerebrovascular Accident
11%
Deep Vein Thrombosis
11%
Disseminated Intravascular Clotting
11%
Edema
22%
Glasgow Coma Scale
11%
Heart Muscle Ischemia
11%
Hematoma
22%
Phase II Trials
11%
Placebo
33%
Rash
11%
Recombinant Blood Clotting Factor 7a
100%
Safety Assessment
11%
Troponin I
11%